"Learning that you have cancer—particularly an incurable cancer—is beyond scary. But every year Cycle for Survival gives me hope that new research will lead to better, more innovative treatments."
- Amy W.
Half of all cancer patients are fighting a rare cancer.
According to the National Institutes of Health (NIH), a "rare cancer" is one with a prevalence of fewer than 200,000 affected individuals in the United States. But when you put all of these rare cancer types together, they account for approximately half of all cancer diagnoses. Research on many rare cancers is drastically underfunded, often leaving patients with limited or no treatment options. Memorial Sloan Kettering Cancer Center—the world’s oldest and largest private cancer center—is committed to changing that reality. MSK’s close collaboration between doctors and researchers is a unique strength: new drugs and therapies developed in the lab can be moved quickly to patients’ bedsides.
Every Dollar Fights Back
"I ride because I know the difference clinical trials and research studies make—for our family the difference was one more year with our mother."
- Rachel B.
Cycle for Survival's indoor team cycling events raise funds that are critical for rare cancer research.
100% of every donation to Cycle for Survival is directly allocated to research at Memorial Sloan Kettering Cancer Center within six months of the events. The donations go to pioneering research and clinical trials, and have already led to new and better treatments for cancer patients worldwide. Memorial Sloan Kettering researchers collaborate with institutions around the world, and have led the way in developing new ways to diagnose and treat cancer. If you want to fight back against cancer, join us!
Thanks to the tremendous efforts of our participants, donors, and supporters, Cycle for Survival has raised over $106.6 million. for rare cancer research, and funded 100+ clinical trials and research studies.
The direct funding has drastically reduced the time it takes for treatments to reach patients—in some cases cutting the span from years to months. Doctors and researchers who have received Cycle for Survival funding credit these resources for making groundbreaking discoveries possible, advancing vital research where—typically—little to no funding exists.
Cycle for Survival will fund these projects in 2012:
Research in the Cancer Biology and Genetics Program
Cancer Biology and Genetics Program scientists are working to determine whether inhibiting a gene called CSF-1R might suppress the development of certain brain tumors called gliomas.
Study of Residual and Recurrent Glioma
Investigators in the Cancer Biology and Genetics Program are studying residual and recurrent glioma to learn more about how brain tumor cells manage to resist conventional therapies.
Comprehensive Molecular Profiling of Ovarian Cancer
Physicians in the Gynecologic Medical Oncology Service are employing comprehensive molecular profiling of low-grade serous and serous borderline ovarian cancer.
New Therapies on Pancreatic Neuroendocrine Tumors
Radiologists are working to develop innovative ways to measure the effects of new therapies on pancreatic neuroendocrine tumors
The Role of New Drug, PD0331991
Scientists in the Molecular Biology Program are exploring the role of a promising new drug, called PDO331991, in the treatment of glioma.
Physicians in the Lymphoma Service are studying innovative new therapies for T-cell lymphomas.
Study Within the Sarcoma Consortium
A study conducted within the sarcoma consortium (a collaboration of 20 clinical centers) has shown that a novel combination of two drugs controls tumor growth better than either drug administered alone. And based on preclinical data made possible by Cycle funds, MSKCC has been approved to begin the first clinical trial to test a drug that inhibits a protein called Aurora Kinase A. The study will have the support of the NCI and will be brought directly into the sarcoma consortium.
Phase II Study of Drug, MK-2206
Physicians in the Head and Neck Medical Oncology Service are conducting a Phase II study of a drug, called MK-2206, in patients with a progressive recurrent/metastatic adenoid cystic carcinoma, a rare cancer that often occurs in the head and neck. .
Genome Sequencing to Study Urothelial Neoplasm
Physicians in the Department of Pathology are using whole genome sequencing a process that determines the complete DNA sequence of an organism’s genome at a single time to study a rare but aggressive cancer called urothelial neoplasm.
|Battle Cry||No one fights alone. This is why we fight back|